for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Clovis Oncology Inc

CLVS.O

Latest Trade

2.79USD

Change

-0.33(-10.45%)

Volume

3,962,968

Today's Range

2.75

 - 

3.11

52 Week Range

2.75

 - 

11.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Clovis Oncology To Highlight Rubraca And Lucitanib Non-Clinical Data At The AACR Virtual Annual Meeting II 2020

* CLOVIS ONCOLOGY TO HIGHLIGHT RUBRACA® (RUCAPARIB) AND LUCITANIB NON-CLINICAL DATA AT THE AACR VIRTUAL ANNUAL MEETING II 2020 Source text for Eikon: Further company coverage:

BRIEF-Clovis Oncology Announces Completion Of Target Enrollment In The Athena Trial, A Phase 3 Maintenance Treatment Study In Front-Line, Newly-Diagnosed Advanced Ovarian Cancer

* CLOVIS ONCOLOGY ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN THE ATHENA TRIAL, A PHASE 3 MAINTENANCE TREATMENT STUDY IN FRONT-LINE, NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER

BRIEF-Clovis Oncology Announces New Recommendations For Rubraca For Treatment Of Metastatic Castration-Resistant Prostate Cancer

* CLOVIS ONCOLOGY - ANNOUNCES NEW RECOMMENDATIONS FOR RUBRACA FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Source text for Eikon: Further company coverage:

BRIEF-Clovis Oncology Announces Pricing Of Public Offering Of Common Stock

* CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Clovis Oncology Announces Proposed Offering Of Common Stock

* CLOVIS ONCOLOGY ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Clovis Oncology Says Price For Rubraca In Prostate Cancer Will Align To Pricing For Ovarian Cancer Indications

* CLOVIS ONCOLOGY - PRICE FOR RUBRACA IN PROSTATE CANCER WILL ALIGN TO PRICING FOR OVARIAN CANCER INDICATIONS

Clovis Oncology's Rubraca gets FDA approval for prostate cancer

Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation.

Clovis Oncology's Rubraca gets U.S. FDA approval for prostate cancer

Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with castration-resistant prostate cancer, whose tumors have a genetic mutation. The approval is for the drug's use in patients whose...

BRIEF-FDA Approves Clovis Oncology's Rubraca For Certain Prostate Cancer Patients

* RUBRACA® (RUCAPARIB) APPROVED IN THE U.S. AS MONOTHERAPY TREATMENT FOR PATIENTS WITH BRCA1/2-MUTANT, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY

BRIEF-Clovis Oncology Announces First Quarter 2020 Operating Results

* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2020 OPERATING RESULTS

BRIEF-Clovis Oncology Says CEO Patrick J. Mahaffy's 2019 Total Compensation Was $6.9 Million

* CLOVIS ONCOLOGY SAYS CEO PATRICK J. MAHAFFY'S 2019 TOTAL COMPENSATION WAS $6.9 MILLION VERSUS $6.3 MILLION IN 2018 – SEC FILING

BRIEF-Clovis Oncology Announces Debt Exchange Transaction

* CLOVIS ONCOLOGY ANNOUNCES DEBT EXCHANGE TRANSACTION Source text for Eikon: Further company coverage:

BRIEF-Clovis Oncology Reports Q4 Loss Per Share $1.81

* Q4 EARNINGS PER SHARE ESTIMATE $-1.71 -- REFINITIV IBES DATA

Clovis Oncology halts mid-stage bladder cancer trial, shares drop

Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 percent.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up